W. Luo

发表

PCN43 ADHERENCE TO GUIDELINES FOR USE OF ERYTHROPOIESIS STIMULATING PROTEINS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA:TRENDS FROM ELECTRONIC MEDICAL RECORDS

M. Stokes, K. Knopf, S. Ross, 2007 .

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, E. Perez, 2014, The New England journal of medicine.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po

R. Gelber, H. Burstein, M. Regan, 2015 .

A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

E. Kohn, E. Winer, W. Barry, 2015 .

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019 .

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Reply to F. Tomao et al

J. Bernhard, M. Regan, P. Francis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

Cesar M. Castro, S. Cannistra, U. Matulonis, 2019, JAMA oncology.

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

William H. Barry, U. Matulonis, N. Horowitz, 2018, Gynecologic Oncology.

PCN112 OFF-LABEL USE OF ONCOLOGY DRUGS IN A COMMUNITY ONCOLOGY EMR DATABASE

K. Knopf, M. Reynolds, K. Fraeman, 2009 .

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

M. Mihm, J. Kirkwood, U. Rao, 2010, American journal of clinical pathology.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

E. Kohn, E. Winer, W. Barry, 2014, The Lancet. Oncology.

Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer

G. Mills, W. Barry, L. Cantley, 2019, International journal of cancer.

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

S. Cannistra, N. Lindeman, U. Matulonis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

G. Mills, E. Winer, M. Berger, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.

S. Cannistra, N. Horowitz, P. Konstantinopoulos, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.

A. Benson, M. Mulcahy, H. Hochster, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

R. Gelber, A. Goldhirsch, J. Bernhard, 2015, The Lancet. Oncology.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

G. Mills, E. Winer, W. Barry, 2019, The Lancet. Oncology.

Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study

S. Landis, S. Shantakumar, B. Nordstrom, 2013, International journal of hypertension.

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

A. Giobbie-Hurder, R. Gelber, A. Goldhirsch, 2020, Breast Cancer Research and Treatment.

Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy

Wei-Chiao Chang, Che-Mai Chang, W. Luo, 2023, Frontiers in Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.

M. Stokes, K. Knopf, R. Nordyke, 2008, Clinical therapeutics.

A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2015 .

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

M. Birrer, S. Cannistra, William H. Barry, 2018, Gynecologic Oncology.

Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2017 .

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of orzel (UFT+leucovorin) in elderly (>=75 years old) patients with colorectal cancer: Results of ECOG 1299

A. Benson, M. Mulcahy, H. Hochster, 2005 .

Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter

R. Nordyke, J. Whyte, B. Nordstrom, 2008, Journal of managed care pharmacy : JMCP.